Survivin gene polymorphism association with papillary thyroid carcinoma

Pathology Research and Practice

Volumn 208, Issue 2, 2012, Pages 100-103

  Yazdani, Nasrin ^a   Sayahpour, Forough A ^b   Haghpanah, Vahid ^b   Amiri, Parvin ^b   Shahrabi Farahani, Maryam ^b   Moradi, Mehran ^a   Mirmiran, Arienne ^b   Khorsandi, Mohammad Taghi ^a   Larijani, Bagher ^a   Mostaan, Leila V ^c   Amoli, Mahsa M ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

31 (G C); Gene polymorphism; Genetics; Survivin; Thyroid cancer

Indexed keywords

ADULT; ALLELE; ARTICLE; CANCER RISK; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; IRAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; SURVIVIN GENE; THYROID PAPILLARY CARCINOMA;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; IRAN; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; THYROID NEOPLASMS;

EID: 84856956183     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2011.12.009     Document Type: Article

References (34)

1. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22(November (53)):8581-8589.
2. Ambrosini G., Adida C., Sirugo G., Altieri D.C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 1998, 273(May (18)):11177-11182.
3. Amoli M.M., Yazdani N., Amiri P., Sayahzadeh F., Haghpanah V., Tavangar S.M., Amirzargar A., Ghaffari H., Nikbin B., Larijani B., Mostaan L.V., Bazzaz J.T. HLA-DR association in papillary thyroid carcinoma. Dis. Markers 2010, 28(1):49-53.
4. Bayram S., Akki{dotless}z H., Bekar A., Akgöllü E. The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011, 35(December (6)):555-559. http://www.ncbi.nlm.nih.gov/pubmed%3Fterm=Bayram%20S%20AND%20survivin.
5. Borges B.D., Burbano R.R., Harada M.L. Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin. Exp. Med. 2011, 11(September (3)):189-193.
6. Dai J., Jin G., Dong J., Chen Y., Xu L., Hu Z., Shen H. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J. Thorac. Oncol. 2010, 5(November (11)):1748-1754.
7. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295(May (18)):2164-2167.
8. Dardano A., Falzoni S., Caraccio N., et al. 1513A>C polymorphism in the P2X7 receptor gene in patients with papillary thyroid cancer: correlation with histological variants and clinical parameters. J. Clin. Endocrinol. Metab. 2009, 94(February (2)):695-698. (United States).
9. Duffy M.J.O., Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett. 2007, 249:4960.
10. Erdogan M., Karadeniz M., Ozbek M., et al. Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population. J. Endocrinol. Invest. (Italy) 2008, 1(September (9)):750-754.
11. Farnebo L., Jedlinski A., Ansell A., Vainikka L., Thunell L.K., Grénman R., Johansson A.C., Roberg K. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int. J. Mol. Med. 2009, 24(October (4)):549-556.
12. Gazouli M., Tzanakis N., Rallis G., Theodoropoulos G., Papaconstantinou I., Kostakis A., Anagnou N.P., Nikiteas N. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int. J. Colorectal Dis. 2009, 24(February (2)):145-150.
13. Haghpanah V., Shooshtarizadeh P., Heshmat R., Larijani B., Tavangar S.M. Immunohistochemical analysis of survivin expression in thyroid follicular adenoma and carcinoma. Appl. Immunohistochem. Mol. Morphol. 2006, 14(December (4)):422-425.
14. Haghpanah V., Khalooghi K., Adabi K., Amiri P., Tavangar S.M., Amirzargar A., Ghaffari H., Yazdani N., Nikbin B., Larijani B., Amoli M.M. Associations between HLA-C alleles and papillary thyroid carcinoma. Cancer Biomarkers 2009, 5(1):19-22.
15. Jang J.S., Kim K.M., Kang K.H., Choi J.E., Lee W.K., Kim C.H., Kang Y.M., Kam S., Kim I.S., Jun J.E., Jung T.H., Park J.Y. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008, 60(April (1)):31-39.
16. Johnson M.E., Howerth E.W. Survivin a binfunctional inhibitor of apoptosis protein. Vet. Pathol. 2004, 41(6):599-607.
17. Kawata N., Tsuchiya N., Horikawa Y., Inoue T., Tsuruta H., Maita S., Sato S., Mitobe Y., Narita S., Habuchi T. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int. J. Cancer 2010, (December (10)). [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed%3Fterm=Kawata%20N%20AND%20survivin.
18. Knauer S.K., Mann W., Stauber R.H. Survivin's dual role: an export's view. Cell Cycle 2007, 6(March (5)):518-521.
19. Krepela E., Dankova P., Moravcikova E., Krepelova A., Prochazka J., Cermak J., Schützner J., Zatloukal P., Benkova K. Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int. J. Oncol. 2009, 35(December (6)):1449-1462.
20. Li F., Ackermann E.J., Bennett C.F., Rothermel A.L., Plescia J., Tognin S., Villa A., Marchisio P.C., Altieri D.C. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1999, 1(December (8)):461-466.
21. Lo Muzio L., Farina A., et al. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett. 2005, 252:27-33.
22. Ma F., Zhang H., Zhai Y., Huang W., Zhao C., Ou S., Zhou H., Yuan W., Wang Z., Wang H., Yue W., Yu L., Li P., Xia X., Cai M., Zhang Y., Cui Y., He F., Ma Y., Zhou G. Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among Chinese. PLoS One 2011, 6(February (2)):e16748.
23. Melet A., Song K., Bucur O., Jagani Z., Grassian A.R., Khosravi-Far R. Apoptotic pathways in tumor progression and therapy. Adv. Exp. Med. Biol. 2008, 615:47-79.
24. Monzó M., Rosell R., Felip E., Astudillo J., Sánchez J.J., Maestre J., Martín C., Font A., Barnadas A., Abad A. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J. Clin. Oncol. 1999, 17(July (7)):2100-2104.
25. Pal T., Vogl F.D., Chappuis P.O., Tsang R., Brierley J., Renard H., Sanders K., Kantemiroff T., Bagha S., Goldgar D.E., Narod S.A., Foulkes W.D. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J. Clin. Endocrinol. Metab. 2001, 86:5307-5312.
26. Srivastava K., Srivastava A., Mittal B. Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol. Biol. Rep. 2011, 1-8.
27. Theodoropoulos G.E., Michalopoulos N.V., Panoussopoulos S.G., Taka S., Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 2010, 39(October (7)):976-980.
28. Upadhyay R., Khurana R., Kumar S., Ghoshal U.C., Mittal B. Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann. Surg. Oncol. 2011, 18(March (3)):880-887.
29. Wagner M., Schmelz K., Dörken B., Tamm I. Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk. Res. 2008, 32(July (7)):1054-1060.
30. Wang Y.H., Chiou H.Y., Lin C.T., Hsieh H.Y., Wu C.C., Hsu C.D., Shen C.H. Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009, 73(March (3)):670-674.
31. Xu Y., Fang F., Ludewig G., Jones G., Jones D. A mutation found in The promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004, 23:419-429.
32. Yang L., Zhu H., Zhou B., Gu H., Yan H., Tang N., Dong H., Sun Q., Cong R., Chen G., Wang B. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig. Dis. Sci. 2009, 54(May (5)):1021-1028.
33. Yang X., Xiong G., Chen X., Xu X., Wang K., Fu Y., Yang K., Bai Y. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2009, 135(October (10)):1341-1349.
34. Yang X., Xiong G., Chen X., Xu X., Wang K., Fu Y., Yang K., Bai Y. Survivin expression in esophageal cancer: correlation with p53 mutations and promoter polymorphism. Dis. Esophagus 2009, 22(3):223-230.